Increasing evidence suggests that ␣-synuclein is a common pathogenic molecule in several neurodegenerative diseases, particularly in Parkinson's disease. To understand ␣-synuclein pathology, we investigated molecules that interact with ␣-synuclein in human and rat brains and identified tubulin as an ␣-synuclein binding-/associated protein. Tubulin co-localized with ␣-synuclein in Lewy bodies and other ␣-synuclein-positive pathological structures. Tubulin initiated and promoted ␣-synuclein fibril formation under physiological conditions in vitro. These findings suggest that an interaction between tubulin and ␣-synuclein might accelerate ␣-synuclein aggregation in diseased brains, leading to the formation of Lewy bodies. The non--amyloid (A)1 component of Alzheimer's disease amyloid, or NAC, originally detected in an amyloid-enriched fraction, was shown to be a fragment of its precursor, NACP, by cloning of the full-length cDNA (1). Later, NACP turned out to be a human homologue of Torpedo synuclein (2). Therefore, it is also referred to as human ␣-synuclein (3). ␣-Synuclein is abundant in presynaptic terminals of neurons (4). Recently, two missense mutations in the ␣-synuclein gene (5) were discovered in certain pedigrees with familial Parkinson's disease and were shown to segregate with the illness (6, 7). Shortly thereafter, ␣-synuclein was identified as the major filamentous component of Lewy bodies (LBs) in Parkinson's disease (8, 9) and of cytoplasmic inclusions in multiple system atrophy (MSA) (10 -12).Thus, ␣-synuclein appears to be a common pathogenic molecule in these diseases.Although the physiological role of ␣-synuclein is unknown, ␣-synuclein has the property of forming fibrils by itself in vitro, and mutations of ␣-synuclein accelerate the fibril formation (13,14). However, the vast majority of cases of neurodegenerative diseases associated with LBs or with ␣-synuclein pathology, such as Parkinson's disease, dementia with Lewy bodies (DLB), MSA, and the LB variant of Alzheimer's disease, are sporadic, where wild-type ␣-synuclein has shown to be abnormally accumulated as fibrillar structures. It is therefore likely that at some stage(s) in the fibril formation of ␣-synuclein, either the nucleation and/or the elongation steps should be somehow accelerated in diseased brains, or alternatively, some degradation process(es) of abnormal structures of ␣-synuclein might be defective in those patients (15).With respect to the amyloidogenesis of Alzheimer's disease, it was demonstrated in vitro that a seed of NAC can accelerate A fibril formation, and conversely, a seed of A can promote NAC fibril formation (16). Similarly, heterogeneous molecules could also be involved in the formation of ␣-synuclein fibrils, leading to pathological structures of ␣-synuclein such as LBs.In this study, we performed a biochemical investigation of molecules that interact with ␣-synuclein in the human brain, and we identified tubulin as one of the ␣-synuclein binding/ associated proteins. This interaction was confirmed by co...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.